Summary of Avalo Therapeutics Conference Call Company Overview - **Company**: Avalo Therapeutics (NasdaqCM:AVTX) - **Event**: 2026 Conference on February 11, 2026 - **Focus**: Discussion on the upcoming phase 2b data from the LOTUS trial for AVTX-009, a monoclonal antibody targeting IL-1 beta Key Points Industry and Product Insights - **Product**: AVTX-009, a high-affinity anti-IL-1 beta monoclonal antibody - **Trial**: LOTUS trial, over 250 patients, placebo-controlled, focusing on moderate to severe hidradenitis suppurativa (HS) [2][36] - **Expected Data Release**: Phase 2b data anticipated in Q2 2026 [2][60] Mechanism of Action - **IL-1 Beta Role**: Principal driver of inflammation in HS, with higher concentrations than other inflammatory markers [6][14] - **Comparison with Other Drugs**: IL-1 beta is considered more effective than IL-1 alpha in treating HS, as evidenced by the failure of anti-IL-1 alpha drugs like bermekimab [13][14] Trial Design and Execution - **Trial Structure**: Three-arm study comparing two dosing regimens of AVTX-009 against placebo [34][35] - **Patient Population**: Over 250 patients enrolled, including a significant number of biologically experienced patients [37][42] - **Placebo Response**: Historical placebo response rates in HS trials range from 13% to 18% [35] Safety and Efficacy Considerations - **Safety Profile**: Expected increase in bacterial infections and potential for neutropenia, but generally manageable [47] - **Efficacy Expectations**: Aiming for a response rate of 20% or higher beyond placebo, with a potential "home run" at 25% [49][50] Future Directions - **Next Steps**: Plans for two pivotal phase III trials following the LOTUS study data [52] - **Potential Indications**: Interest in expanding into dermatology, rheumatology, and gastrointestinal diseases due to the potency of AVTX-009 [53] Financial Position - **Cash Reserves**: $100 million reported at the end of the previous year, with a burn rate of $50 million [68] Additional Considerations - **Quality of Life Metrics**: Focus on pain relief and quality of life improvements as key endpoints in the trial [54][55] - **Data Release Timeline**: Complete data set expected to include a 6-week safety follow-up, with final patient visits concluding in March 2026 [62][64] This summary encapsulates the critical insights from the Avalo Therapeutics conference call, highlighting the company's strategic focus, product development, and market positioning within the biotech industry.

Summary of Avalo Therapeutics FY Conference Call (December 02, 2025) Company Overview - **Company**: Avalo Therapeutics (NasdaqCM:AVTX) - **Focus**: Development of AVTX-009 for hidradenitis suppurativa (HS) Key Points Industry Context - **2025 Performance**: The year was described as exciting, with expectations for 2026 to be even more promising [4][5] - **Competitor Landscape**: Mention of Lutikismab, a competitor in the HS market, currently in phase 3 studies [49] Clinical Trial Updates - **LOTUS Trial**: - Phase 2 trial for HS with AVTX-009 has completed enrollment as of October 29, 2025, exceeding the target of 222 patients, reaching 250 [6][16] - The trial is designed to show a 20% delta difference in HiSCR75 on a placebo-adjusted basis with 80% power, and 90% power for a 25-30% difference [16][18] - Top-line data expected in Q2 2026, following a 16-week treatment duration and a six-week follow-up [10][11][12] Trial Design and Execution - **Demographics**: The trial includes a higher proportion of biologically experienced patients, with over a third expected to be biologically experienced [21][22] - **Site Management**: - Approximately 90 sites involved, primarily in the U.S. and Canada, with rigorous site qualification and training processes implemented [29][30] - Emphasis on managing the placebo effect through strict protocols and training for both investigators and patients [30][35] Future Development Plans - **Phase 3 Trials**: - The anchor dose for the phase 3 program will likely be one of the two doses tested in phase 2, with a preference for a more patient-friendly dosing schedule [43][44] - Discussions with the FDA will determine the need for additional dose-ranging studies [44][45] Competitive Positioning - **Differentiation from Lutikismab**: - AVTX-009 is expected to offer a longer dosing interval and potentially higher efficacy due to its higher potency [49][51] - The company aims to demonstrate a benign side effect profile similar to Lutikismab while exploring efficacy in various patient populations [52][56] Financial Considerations - **Capital Needs**: Significant capital will be required for two large phase 3 trials, with expectations of strong investor interest due to the drug's potential [58] - **Expansion Opportunities**: Potential to explore other indications related to IL-1 beta, including dermatology and rheumatology [59] Conclusion - **Outlook**: The company is optimistic about the upcoming data and its potential impact on the market, with a strong focus on execution and differentiation in a competitive landscape [62]

Summary of Avalo Therapeutics FY Conference Call Company Overview - **Company**: Avalo Therapeutics (NasdaqCM:AVTX) - **Location**: Near Philadelphia - **New Asset**: AVTX-009, a high affinity human anti-IL-1 beta monoclonal antibody targeting hidradenitis suppurativa (HS) [2][3] Key Points Product Development - **Background**: AVTX-009 was originally developed by Lilly for type 2 diabetes, showing a moderate effect size of 0.25-0.3 grams reduction in hemoglobin A1C, but was not pursued further [2][3] - **Acquisition**: Avalo acquired the asset after it was not advanced by previous owners [3] - **Funding**: The company raised $185 million in 2024 to support its operations and trials [3] - **Lotus Trial**: A phase 2b proof of concept study for AVTX-009 is fully enrolled, with data expected in mid-2026 [4] Mechanism of Action - **IL-1 Beta Role**: IL-1 beta is a master regulator of the immune system, crucial in the inflammatory response in HS lesions [5][6] - **Cytokine Levels**: IL-1 beta is the most abundant cytokine in HS lesions, making it a prime target for treatment [7] Comparison with Competitors - **AbbVie’s Lutikizumab**: A bispecific anti-IL-1 beta and anti-IL-1 alpha drug with a shorter half-life and lower affinity for IL-1 beta compared to AVTX-009 [11][12] - **Efficacy Data**: AbbVie reported a drug effect size of approximately 46% in a severe HS population, which Avalo aims to exceed with its higher affinity drug [13][15] Trial Design and Expectations - **Placebo Response**: The Lotus trial is designed to mitigate placebo responses, with a conservative estimate of a 20% placebo rate based on historical data [19][20] - **Patient Demographics**: The trial includes a mix of biologically experienced patients, with a higher proportion of TNF and IL-17 failures compared to competitors [25][26] Future Indications - **Exploration Beyond HS**: Avalo is interested in expanding indications to include crystal arthropathies, such as gout, in addition to other inflammatory conditions [30][31] Financial Health - **Balance Sheet**: Avalo has $115 million available, sufficient to fund operations through data release and into 2028, with plans to raise funds for phase three trials [33] Additional Insights - **Trial Management**: The company emphasizes rigorous training for investigators to ensure objective assessments and accurate data collection [27][28] - **Statistical Approach**: Avalo plans to handle non-responder imputation scientifically, contrasting with other companies' methods that may artificially lower efficacy results [29]